Samad Azari1, Aziz Rezapour2, Negar Omidi3, Vahid Alipour4, Masoud Behzadifar5, Hossein Safari4, Masih Tajdini3, Nicola Luigi Bragazzi6. 1. Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran. 2. Health Management and Economics Research Center, School of Health Management and Information Sciences, Iran University of Medical Sciences, Rashid Yasemi Street, Upper than Mirdamad St, Tehran, Iran. rezapour.a@iums.ac.ir. 3. Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. 4. Health Management and Economics Research Center, School of Health Management and Information Sciences, Iran University of Medical Sciences, Rashid Yasemi Street, Upper than Mirdamad St, Tehran, Iran. 5. Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran. 6. School of Public Health, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
Abstract
AIMS: To assess the cost-effectiveness of pro-protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in cardiovascular disease. METHODS AND RESULTS: We performed a comprehensive search strategy in electronic databases from January 2015 to January 2019. Out of 475 articles, 16 were entered into the study. Quality-adjusted life year, life years gained (LYG), annual cost, and the incremental cost-effectiveness ratio (ICER) regarding the use of PCSK9 inhibitors were considered as the key outcomes. The cost-effectiveness threshold varied from $45,000 in Spain to $150,000 in the USA. The annual cost of PCSK9 inhibitors for studies undertaken in the USA was in the range of $14,000 to $15,000, while it was about $7000 for other developed countries. The results showed that reduction in the price of PCSK9 inhibitors changed from 20 to 88%. The means of QALY were 0.65 and 0.67 in the Markov and Cardiovascular Disease Policy Modeling (CVDPM) models; also, the ICER means were $197,707 and $625,555 for the Markov and CVDPM model, respectively. CONCLUSION: According to the current study, the effectiveness of PCSK9 inhibitors is well documented, although all studies pointed out a higher cost of these inhibitors. TRIAL REGISTRATION: This study was registered within the International Prospective Register of Systematic Reviews (PROSPERO) database of the University of York (CRD42018088472).
AIMS: To assess the cost-effectiveness of pro-protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in cardiovascular disease. METHODS AND RESULTS: We performed a comprehensive search strategy in electronic databases from January 2015 to January 2019. Out of 475 articles, 16 were entered into the study. Quality-adjusted life year, life years gained (LYG), annual cost, and the incremental cost-effectiveness ratio (ICER) regarding the use of PCSK9 inhibitors were considered as the key outcomes. The cost-effectiveness threshold varied from $45,000 in Spain to $150,000 in the USA. The annual cost of PCSK9 inhibitors for studies undertaken in the USA was in the range of $14,000 to $15,000, while it was about $7000 for other developed countries. The results showed that reduction in the price of PCSK9 inhibitors changed from 20 to 88%. The means of QALY were 0.65 and 0.67 in the Markov and Cardiovascular Disease Policy Modeling (CVDPM) models; also, the ICER means were $197,707 and $625,555 for the Markov and CVDPM model, respectively. CONCLUSION: According to the current study, the effectiveness of PCSK9 inhibitors is well documented, although all studies pointed out a higher cost of these inhibitors. TRIAL REGISTRATION: This study was registered within the International Prospective Register of Systematic Reviews (PROSPERO) database of the University of York (CRD42018088472).
Authors: Achim Leo Burger; Edita Pogran; Marie Muthspiel; Christoph Clemens Kaufmann; Bernhard Jäger; Kurt Huber Journal: Biomedicines Date: 2022-04-22
Authors: Ahmed Alghamdi; Bander Balkhi; Abdulaziz Altowaijri; Nasser Al-Shehri; Lewis Ralph; Emily-Ruth Marriott; Michael Urbich; Fawaz Aljanad; Rima Aziziyeh Journal: Pharmacoecon Open Date: 2021-09-28